HealthcareRequest a quote Oral solids · Contract manufacturing enquiry
Discuss third-party manufacturing with Walter Healthcare, India. Confirm the formulation, tablet presentation, packaging and project requirements for a product-specific quotation.
Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.
Editorial development perspective
These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.
A matching clinical reference has not yet been verified for this page. Drug-specific mechanisms and human pharmacokinetic values remain open for review.
Listed presentation: Tablets.
Use early development batches to compare blend flow, compression behaviour, tablet strength and the appropriate release test. A harder tablet or a faster disintegration result is not, by itself, a complete product specification. Set priorities around the intended presentation, then check that the chosen process can reproduce them at the proposed scale.
Catalogue wording: “SR”.
Define the intended release profile and its test method before choosing a coating, matrix or other formulation approach. Compare prototypes against that target and identify the formulation-specific evidence needed to assess exposure and food effects. A release abbreviation alone does not establish a duration of action, dosing interval or pharmacokinetic profile.
Strength expressions in this entry include “400 mg”.
Tie every stated ingredient amount to its intended dosage unit or measure, then distinguish that declared amount from the quantity of raw material needed for a batch. Record any assay or equivalence calculation in the formula. This gives development, purchasing and artwork teams the same strength definition without assigning a patient dose from the catalogue.
A practical starting point is to make the release target explicit. For this tablets brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.
Discuss this product briefManufacturing & packaging brief
Use this preparation guide for Flupirtine Maleate 400 mg (SR) Uncoated Tablets. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.
Define release type, coating, scoring and any reference-product requirements. Keep each strength and presentation as a separate item in the brief.
Agree the product specification, analytical methods and applicable dissolution or disintegration requirements. Identify the formula and process information available for transfer.
Review the technical documentsCompare the proposed blister, strip or bottle with the formulation and its protection requirements. Specify tablets per primary pack and primary packs per carton.
Explore packaging optionsFor Flupirtine Maleate 400 mg (SR) Uncoated Tablets, state the tablet count and finished-pack count, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.
Explore the context
Common questions
Flupirtine Maleate 400 mg (SR) Uncoated Tablets
The catalogue lists Flupirtine Maleate 400 mg (SR) Uncoated as tablets in its pain & musculoskeletal care navigation area and non-beta-lactam manufacturing stream.
No. Walter checks current facility permissions, formulation and equipment fit, testing, packaging and target-market requirements before written confirmation.
Share the exact composition and strength, tablets presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.
The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.
Include each proposed pack and country in the enquiry. Container compatibility, artwork, supporting stability evidence, permission scope and destination requirements need review for the requested configuration.
A catalogue record does not establish export registration or a shelf-life commitment.
Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.
Technical document review
Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.
Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.
Important qualification
This B2B catalogue record is not proof of current approval or confirmation that Flupirtine Maleate 400 mg (SR) Uncoated Tablets is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.
Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .